This pattern of expression makes the targeting of CD1a fratricide-free and with limited on-target off-tumor effects supporting the idea of a personalized immunotherapeutic option for that sub-population of T-ALL patients, even rarely expressing CD1a [15]. This evidence concerns the gene CD1A and acute lymphoblastic leukemia.